Elevation Oncology’s (ELEV) “Market Perform” Rating Reaffirmed at William Blair

Elevation Oncology (NASDAQ:ELEV – Get Free Report)‘s stock had its “market perform” rating reaffirmed by research analysts at William Blair in a note issued to investors on Monday,Benzinga reports. Other research analysts have also issued reports about the company. Piper Sandler lowered Elevation Oncology from an “overweight” rating to a “neutral” rating and lowered their […]

Leave a Reply

Your email address will not be published.

Previous post Mizuho Begins Coverage on Etoro Group (NASDAQ:ETOR)
Next post Tariff tensions force Spain’s food giants to seek markets beyond the US